【摘要】 目的探讨沙利度胺联合FOLFOX4方案治疗晚期原发性肝癌的疗效。方法选择晚期原发性肝癌患者62例为研究对象,随机分为观察组和对照组,观察组患者接受沙度利胺联合FOLFOX4化疗方案,对照组患者接受FOLFOX4化疗方案,比较2组患者的近期疗效、不良反应发生率及治疗前后AFP的水平。结果观察组治疗有效率及疾病控制率均明显高于对照组,差异具有统计学意义(P<0.05)。2组患者骨髓抑制、消化道反应、神经毒性、嗜睡、乏力、便秘、皮疹等不良反应的发生率差异无统计学意义(P>0.05)。治疗后,2组患者血清的AFP水平均明显降低(P<0.05),且观察组患者AFP的水平明显低于对照组治疗后的水平(P<0.05)。结论沙利度胺联合FOLFOX4化疗方案治疗晚期原发性肝癌可明显提高有效率和疾病控制率,降低患者AFP水平,毒副作用可耐受,值得在临床上推广应用。更多还原

【Abstract】 Objective To investigate the efficacy of thalidomide combined with FOLFOX4 for advanced hepatocellular carcinoma. Methods 62 patients with advanced primary liver cancer were enrolled in the study. 62 patients were randomly divided into the observation group and the control group,the observation group received thalidomide combined with FOLFOX4 treatment and the control group received FOLFOX4 treatment. The short-term efficacy,incidence of adverse reactions after treatment and the AFP level of the 2 groups were compared. Results Disease control rate of the observation group were significantly higher than those of the control group,there had statistically significant difference( P < 0. 05). The incidence of bone marrow suppression,gastrointestinal reactions,peripheral neurotoxicity,drowsiness,fatigue,constipation and rash of the 2 groups had no significant difference( P > 0. 05). The AFP level in the observation group after treatment was significantly lower than before treatment( P <0. 05). AFP level in the control group were also significantly lower than before treatment( P < 0. 05). After treatment,AFP level in the observation group were significantly lower than those of the control group after treatment( P < 0. 05). Conclusion Thalidomide combined with FOLFOX4 can significantly improve treatment efficiency and disease control rate of primary liver cancer,reduce AFP level. The side effects can be tolerated,which is worthy of clinical application.更多还原